XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference

VALLEY COTTAGE, New York, September 6 XTLBiopharmaceuticals Ltd. (NASDAQ: XTLB, LSE: XTL, TASE: XTL) announced todaythat a late breaker abstract, entitled "Potent Small Molecule HCV InhibitorsAffecting NS5A-dependent Functions," was selected for oral presentation atthe 14th International Symposium on Hepatitis C Virus & Related Viruses(http://www.hcv2007.com/).

The presentation will take place at 10:30 Greenwich Mean time onThursday, September 13, 2007, and a press release outlining the datapresented will be released by the Company shortly thereafter.

The compounds that will be presented at the conference emerged from theCompany's DOS program, aimed at discovering novel hepatitis C inhibitorsapplying a unique chemistry technology called Diversity Oriented Synthesis.The DOS program was acquired by the Company in late 2005.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development oftherapeutics for the treatment of neuropathic pain and hepatitis C. XTL isdeveloping Bicifadine, a serotonin and norepinephrine reuptake inhibitor, forthe treatment of diabetic neuropathic pain. XTL is also developing severalnovel pre-clinical hepatitis C small molecule inhibitors. XTL also has anactive in-licensing and acquisition program designed to identify and acquireadditional drug candidates. XTL is publicly traded on the NASDAQ, London, andTel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).Contact: Ron Bentsur Chief Executive Officer Tel: +1-845-267-0707 ext. 225

SOURCE XTL Biopharmaceuticals Ltd

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...